Jannah Theme License is not validated, Go to the theme options page to validate the license, You need a single license for each domain name.

Participated in Aptose, Cantor Oncology, Hematology & HemeOnc Conferences, The Canadian Business Journal

SAN DIEGO & TORONTO, Sept. 14, 2022 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS) develops highly differentiated oral medicines A clinical-stage precision oncology company. Aptose, a kinase inhibitor for treating hematologic malignancies, today announced that he will be attending the Cantor Oncology, Hematology & HemeOnc Conference on September 28, 2022.

Aptose’s Chief Medical Officer, Dr. Rafael Bejar, will join a panel discussion.Leukemia and MDS’ and Aptose CFO Fletcher Payne will host one-on-one meetings during the conference. Contact your meeting representative to schedule his one-on-one meeting with Aptose management.

Cantor Oncology, Hematology & HemeOnc Conference
date: September 28, 2022
Presentation time: 3:25 PM ET
format: Panel presentation
participant: Rafael Bejar, MD, Ph.D., Senior Vice President, Chief Medical Officer

About Aptose

Aptose Biosciences is a clinical-stage biotechnology company focused initially on hematology and committed to developing personalized therapies to address unmet medical needs in oncology. Our small molecule oncology pipeline includes products designed to provide single-agent efficacy and enhance the efficacy of other anticancer therapies and regimens without overlapping toxicity. I’m here. We have two clinical-stage investigational drugs in development for hematologic malignancies. Luxeptinib, an oral, dual lymphoid and myeloid kinome inhibitor, is in a Phase 1a/b study in patients with relapsed or refractory B-cell malignancies and another Phase 1a/ bPatients with relapsed or refractory AML or high-risk myelodysplastic syndrome (MDS) in the study. For more information, please visit www.aptose.com.

Forward-Looking Statements

This press release may contain forward-looking statements within the meaning of Canadian and US securities laws. This includes, but is not limited to, statements regarding the company’s growth, plans, objectives, expectations, intentions and other statements containing words such as “continue”. , “expect”, “intend”, “will”, “hope”, “should”, “would”, “may”, “could” and other similar expressions. Such statements reflect our current views regarding future events, are subject to risks and uncertainties and are necessarily based on many estimates and assumptions. Social uncertainty and unforeseen circumstances. A number of factors could cause actual results, performance or achievements to differ materially from the future results, performance or achievements described in this press release.

If one or more of these risks or uncertainties materializes or the assumptions set forth in the section entitled “Risk Factors” of our filings with the Canadian securities regulators and the U.S. Securities and Exchange Commission , if proven to be the basis of these forward-looking statements, actual results may differ materially from those set forth herein. These forward-looking statements are made as of the date of this press release and we do not intend and do not intend to update these forward-looking statements except as required by law. assume no obligations. Since actual results and future events could differ materially from those anticipated in such statements, no assurance can be given that such statements will prove to be accurate. Please note that forward-looking statements are not guarantees of future performance. Accordingly, investors are cautioned not to place undue reliance on forward-looking statements as they are inherently uncertain.

For more information, please contact:

CBJ Newsmaker

Participated in Aptose, Cantor Oncology, Hematology & HemeOnc Conferences, The Canadian Business Journal

Source link Participated in Aptose, Cantor Oncology, Hematology & HemeOnc Conferences, The Canadian Business Journal

Related Articles

Back to top button